Search International and National Patent Collections

1. (WO2018218877) MALIGNANT GLIOMA CAR-T THERAPEUTIC VECTOR BASED ON OCTS TECHNOLOGY, AND CONSTRUCTION METHOD AND APPLICATION THEREOF

Pub. No.:    WO/2018/218877    International Application No.:    PCT/CN2017/110670
Publication Date: Fri Dec 07 00:59:59 CET 2018 International Filing Date: Tue Nov 14 00:59:59 CET 2017
IPC: C12N 15/867
C12N 15/62
C12N 15/10
A61K 35/17
A61P 35/00
Applicants: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD
上海优卡迪生物医药科技有限公司
Inventors: QI, Wei
祁伟
YU, Lei
俞磊
KANG, Liqing
康立清
LIN, Gaowu
林高武
YU, Zhou
余宙
Title: MALIGNANT GLIOMA CAR-T THERAPEUTIC VECTOR BASED ON OCTS TECHNOLOGY, AND CONSTRUCTION METHOD AND APPLICATION THEREOF
Abstract:
Provided is a malignant glioma CAR-T therapeutic vector based on OCTS technology, comprising a lentiviral skeleton plasmid, a human EF1α promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and PDL1 single chain antibodies, the OCTS chimeric receptor structural domain comprising: a CD8 leader chimeric signal peptide (SEQ ID NO. 15); PDL1 single chain antibody light chain VL (SEQ ID NO. 16) and PDL1 single chain antibody heavy chain VH (SEQ ID NO. 17); EGFRvIII single chain antibody light chain VL (SEQ ID NO. 18) and EGFRvIII single chain antibody heavy chain VH (SEQ ID NO. 19); an antibody Inner-Linker (SEQ ID NO. 20); a single chain antibody Inter-Linker (SEQ ID NO. 21); a CD8 Hinge chimeric receptor hinge (SEQ ID NO. 22); a CD8 Transmembrane chimeric receptor transmembrane region (SEQ ID NO. 23); a TCR chimeric receptor T-cell activation domain (SEQ ID NO. 26); and a chimeric receptor costimulatory factor region. Also provided are a construction method for the vector and an application thereof for preparing a drug for the treatment of malignant glioma.